Lv79
4470 积分 2022-08-26 加入
New BTK Inhibitors May Combat Resistance in CLL
13天前
已完结
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
19天前
已完结
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
21天前
已完结
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
1个月前
已完结
The treatment of marginal zone lymphoma
1个月前
已完结
The biology of marginal zone lymphoma subtypes: challenge and relevance of classification
1个月前
已完结
Drug development in MZL: caring for the forgotten child
1个月前
已完结
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
2个月前
已完结
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
2个月前
已完结
Seamless phase 2/3 oncology trial design with flexible sample size determination
2个月前
已完结
皖公网安备34019202002308
